Home » Ligand to Acquire Neurogen for Stock, Contingent Value Rights
Ligand to Acquire Neurogen for Stock, Contingent Value Rights
Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced Monday they have entered into a definitive merger agreement under which Ligand will acquire Neurogen.
Earth Times
Earth Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May